title: Drifting agenda for federal treatment research.
authors.forename: B
authors.initials: B
authors.lastname: Huff
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002219:Carbamates; D002986:Clinical Trials as Topic; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005380:Financing, Government; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D009316:National Institutes of Health (U.S.); D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D014481:United States; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D015224:Dideoxynucleosides; D005663:Furans; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D000099227:Abacavir; C095108:amprenavir